| Literature DB >> 31738794 |
Odunayo I Azeez1,2, Jan G Myburgh3, Ana-Mari Bosman4, Jonathan Featherston5, Kgomotso P Sibeko-Matjilla4, Marinda C Oosthuizen4, Joseph P Chamunorwa1.
Abstract
BACKGROUND: Concerted efforts to identify the pathogenesis and mechanism(s) involved in pansteatitis, (a generalized inflammation of the adipose tissue), that was attributed to the recent crocodile die off in the Olifants River and Loskop Dam in Kruger National Park, Mpumalanga, South Africa have been in the forefront of research in recent time. As part of the efforts, molecular characterization of healthy and pansteatitis adipose tissue was carried out by RNA sequencing (RNA-Seq) using Next Generation Sequencing (NGS) and de novo assembly of the adipose transcriptome, followed by differential gene expression analysis.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31738794 PMCID: PMC6861000 DOI: 10.1371/journal.pone.0225073
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Summary of the Nile crocodile de novo transcriptome statistics.
| Sequence Parameters | Value | Sequence Parameters | Value |
|---|---|---|---|
| Total sequences | 406, 060 | GC content | 43.91988 |
| Total Transcripts | 40, 201 | Overall Score of the assembly | 0.3171227 |
| Smallest seq (bp) | 201 | GC_skew | 1.049384 |
| Largest seq (bp) | 23464 | AT_skew | -1.880586 |
| Total no of bases | 1.704537e+008 | CPG ratio | 1.351256 |
| Mean Seq length | 419.7747 | Fragments | 8090858 |
| Seq under 200 bp | 0 | Fragments mapped | 6189278 |
| Seq over 1000 bp | 21, 276 | % Fragments mapped | 76.49718 |
| Seq over 10,000 bp | 46 | Good mappings | 4,912,937 |
| No of Sequences with ORF | 82,119 | % Good mapping | 60.72208 |
| Mean ORF percentage | 51.39 | Bad mappings | 1,276,341 |
| Contigs containing 90% of bases (N90) | 221 | Potential Bridges | 11010 |
| Contigs containing 70% of bases (N70) | 298 | Bases uncovered | 6,809,699 |
| Contigs containing 50% of bases (N50) | 436 | % Bases uncovered | 3.995043 |
| Contigs containing 30% of bases (N30) | 772 | CRBB hits | 22546 |
| Reciprocal Blast Hit (RBH) per reference | 1.684297 | % Refs with CRBB | 67.04766 |
| Cut off score | 0.2557338 | Optimal Score | 0.3792041 |
Comparison of GC content and N50 of assembled transcriptomes of selected non-model organisms.
| Organism | |||||||
|---|---|---|---|---|---|---|---|
| Chordata | Chordata | Cnidaria | Chordata | Mollusca | Ctenophora | Annelida | |
| 53.95 | 43.92 | 31.24 | 45.39 | 36.55 | 51.66 | 40.53 | |
| 2447 | 436 | 1854 | 467 | 2,876 | 2373 | 1,949 |
* Current study
Fig 1Comparison of GC contents of the transcriptomes from selected vertebrates including humans.
Note that Alligators and crocodiles have similar and highest GC content [5], http://genomebiology.com/2012/13/1/415.
Fig 2Gene ontology classification of the assembled transcripts of the Nile crocodile showing the percentages of genes involved in various biological functions.
Fig 3Gene ontology classification of the assembled transcripts of the Nile crocodile from the de novo transcriptome assembly showing the percentages of genes involved in various molecular functions.
Fig 4Gene ontology of the assembled transcripts of the Nile crocodile from the de novo transcriptome assembly showing the classification of the various protein transcripts.
Gene ontology functional classification of the total transcripts after de novo assembly, according to pathways.
| Pathways | No of pathways | % of total genes | |
|---|---|---|---|
| 1 | Parkinson disease (P00049) | 3 | 7.7 |
| 2 | Angiogenesis (P00005) | 2 | 5.1 |
| 3 | Vasopressin synthesis (P04395) | 2 | 5.1 |
| 4 | Blood coagulation (P00011) | 2 | 5.1 |
| 5 | T cell activation (P00053) | 2 | 5.1 |
| 6 | TCA cycle (P00051) | 2 | 5.1 |
| 7 | Methionine biosynthesis (P02753) | 1 | 2.6 |
| 8 | Tryptophan biosynthesis (P02783) | 1 | 2.6 |
| 9 | Axon guidance mediated by Slit/Robo (P00008) | 1 | 2.6 |
| 10 | Opioid prodynorphin pathway (P05916) | 1 | 2.6 |
| 11 | Integrin signaling pathway (P00034) | 1 | 2.6 |
| 12 | Adrenaline and noradrenaline biosynthesis (P00001) | 1 | 2.6 |
| 13 | Inflammation mediated by chemokine and cytokine signaling pathway (P00031) | 1 | 2.6 |
| 14 | Dopamine receptor mediated signaling pathway (P05912) | 1 | 2.6 |
| 15 | Angiotensin II-stimulated signaling through G proteins and beta-arrestin (P05911) | 1 | 2.6 |
| 16 | Gonadotropin releasing hormone receptor pathway (P06664) | 1 | 2.6 |
| 17 | Vitamin D metabolism and pathway (P04396) | 1 | 2.6 |
| 18 | PDGF signaling pathway (P00047) | 1 | 2.6 |
| 19 | Cytoskeletal regulation by Rho GTPase (P00016) | 1 | 2.6 |
| 20 | Nicotine pharmacodynamics pathway (P06587) | 1 | 2.6 |
| 21 | Cholesterol biosynthesis (P00014) | 1 | 2.6 |
| 22 | B cell activation (P00010) | 1 | 2.6 |
| 23 | CCKR signaling map (P06959) | 1 | 2.6 |
| 24 | Heme biosynthesis (P02746) | 1 | 2.6 |
| 25 | Pyruvate metabolism (P02772) | 1 | 2.6 |
| 26 | Heterotrimeric G-protein signaling pathway-rod outer segment phototransduction (P00028) | 1 | 2.6 |
| 27 | Flavin biosynthesis (P02741) | 1 | 2.6 |
| 28 | Wnt signaling pathway (P00057) | 1 | 2.6 |
| 29 | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway (P00026) | 1 | 2.6 |
| 30 | VEGF signaling pathway (P00056) | 1 | 2.6 |
| 31 | Ascorbate degradation (P02729) | 1 | 2.6 |
| 32 | Plasminogen activating cascade (P00050) | 1 | 2.6 |
Fig 5Volcano plot of expressed transcripts as determined by RSEM/EBseq.
Blue dots indicate significantly higher expressed genes in pansteatitis as compared to healthy adipose tissues. Blue dots to the right side of zero on the x axis indicate the upregulated genes while those on the right show the downregulated genes.
Fig 6Gene ontology classification of upregulated differentially expressed genes in pansteatitis according to the protein types.
Fig 7Gene ontology classification of up-regulated genes according to their molecular functions.
Functional classification of the upregulated genes according to the pathways they influence and control.
| Pathway | No of genes | Percentage | ||
|---|---|---|---|---|
| 1 | Gonadotropin-releasing hormone receptor pathway (P06664) | 11 | CTNNB1, IGF1R, ITGB1, NR3C1, PIK3R1, STAT3, VCL, BMPR2, RAC1 | 16.7% |
| 2 | Integrin signaling pathway (P00034) | 7 | ARPC2, PIK3C2A, ITGB1, PIK3R1, VCL, RAC1, | 10.6% |
| 3 | Inflammation mediated by chemokine and cytokine signaling pathway (P00031) | 6 | ARPC2, ITGB1, MYH9, MYH10, STAT3, RAC 1 | 9.1% |
| 4 | EGF receptor signaling pathway (P00018) | 6 | YWHAH, PIK3C2A, YWHAQ, GAB1, STAT3, RAC1 | 9.1% |
| 5 | CCKR signaling map (P06959) | 6 | CTNNB1, PIK3C2A, JAK1, PIK3R1, STAT3 | 9.1% |
| 6 | Angiogenesis (P00005) | 5 | CTNNB1, ITGB1, PIK3R1, STAT3, RAC1 | 7.6% |
| 7 | Cytoskeletal regulation by Rho GTPase (P00016) | 5 | ARPC2, MYH9, MYH10, RAC1 | 7.6% |
| 8 | FGF signaling pathway (P00021) | 4 | YWHAH, PIK3C2A, YWHAQ, RAC1 | 6.1% |
| 9 | PDGF signaling pathway (P00047) | 4 | JAK1, GAB1, PIK3R1, STAT3 | 6.1% |
| 10 | Axon guidance mediated by netrin (P00009) | 3 | PIK3C2A, PIK3R1, RAC1 | 4.5% |
| 11 | Insulin/IGF pathway-protein kinase B signaling cascade (P00033) | 3 | PIK3C2A, IGF1R, PIK3R1 | 4.5% |
| 12 | p53 pathway (P00059) | 3 | HMGB1, PIK3C2A,PIK3R1 | 4.5% |
| 13 | p53 pathway feedback loops 2 (P04398) | 3 | CTNNB1, PIK3C2A, PIK3R1 | 4.5% |
| 14 | VEGF signaling pathway (P00056) | 3 | PIK3C2A, PIK3R1, RAC1 | 4.5% |
| 15 | T cell activation (P00053) | 3 | PIK3R1, RAC1 | 4.5% |
| 16 | JAK/STAT signaling pathway (P00038) | 2 | JAK1, STAT3 | 3.0% |
| 17 | Interleukin signaling pathway (P00036) | 2 | STAT3 | 3.0% |
| 18 | Hypoxia response via HIF activation (P00030) | 2 | PIK3C2A, PIK3R1 | 3.0% |
| 19 | Ras Pathway (P04393) | 2 | STAT3, RAC1 | 3.0% |
| 20 | TGF-beta signaling pathway (P00052) | 2 | TGFBR2, BMPR2 | 3.0% |
| 21 | Endothelin signaling pathway (P00019) | 2 | PIK3C2A, PIK3R1 | 3.0% |
| 22 | Parkinson disease (P00049) | 2 | YWHAH, YWHAQ | 3.0% |
| 23 | p38 MAPK pathway (P05918) | 2 | IL1R1, RAC1 | 3.0% |
| 24 | Nicotinic acetylcholine receptor signaling pathway (P00044) | 2 | MYH9, MYH10 | 3.0% |
| 25 | Axon guidance mediated by Slit/Robo (P00008) | 1 | RAC1 | 1.5% |
| 26 | Axon guidance mediated by semaphorins (P00007) | 1 | RAC1 | 1.5% |
| 27 | Apoptosis signaling pathway (P00006) | 1 | 1.5% | |
| 28 | Alzheimer disease-presenilin pathway (P00004) | 1 | CTNNB1 | 1.5% |
| 29 | Interferon-gamma signaling pathway (P00035) | 1 | JAK1 | 1.5% |
| 30 | Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade (P00032) | 1 | IGF1R | 1.5% |
| 31 | Nicotine pharmacodynamics pathway (P06587) | 1 | PPP1CB | 1.5% |
| 32 | Huntington disease (P00029) | 1 | RAC1 | 1.5% |
| 33 | Wnt signaling pathway (P00057) | 1 | CTNNB1 | 1.5% |
| 34 | PI3 kinase pathway (P00048) | 1 | PIK3R1 | 1.5% |
| 35 | Cadherin signaling pathway (P00012) | 1 | CTNNB1 | 1.5% |
| 36 | Dopamine receptor mediated signaling pathway (P05912) | 1 | PPP1CB | 1.5% |
| 37 | B cell activation (P00010) | 1 | RAC1 | 1.5% |
Note:
* indicates pathways that are part of Toll-like receptor, inflammation and NFkB signaling.
# indicates pathways that are part of apoptosis pathways.
Fig 8Gene ontology of the downregulated genes, showing their biological functions.
Fig 9Gene ontology of down regulated genes in pansteatitis showing their protein classification.